Frankfurt - Delayed Quote EUR

Pharming Group N.V. (PHGN.F)

0.8810

+0.0860

+(10.82%)

At close: May 9 at 8:03:53 AM GMT+2

Pharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...

Pharming Group (PHGUF) reports a 42% revenue increase, driven by Ruconest and Joenja sales, while navigating acquisition costs and potential tariff challenges.

GuruFocus.com 21 hours ago

PHARM.AS
Pharming Group reports first quarter 2025 financial results and provides business update

First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating prof

GlobeNewswire yesterday

PHAR

PHGUF
Earnings To Watch: Pharming Group (PHGUF) Reports Q1 2025 Result

Pharming Group (PHGUF) is set to release its Q1 2025 earnings on May 8, 2025. The consensus estimate for Q1 2025 revenue is $67.74 million, and the earnings are expected to come in at -$0.03 per share. Revenue estimates for Pharming Group (PHGUF) have increased from $310.45 million to $326.76 million for the full year 2025 and from $336.53 million to $358.84 million for 2026 over the past 90 days.

GuruFocus.com 2 days ago

PHARM.AS
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decided to nominate Dr. Elaine Sul

GlobeNewswire 9 days ago

PHAR

PHGUF
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)

GlobeNewswire 14 days ago

PHAR

PHGUF
SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 14 days ago

PHARM.AS
Pharming announces positive recommendation from NICE for Joenja

Pharming (PHAR) Group announced overnight that the National Institute for Health and Care Excellence has issued positive final guidance recommending Joenja for reimbursement and use within the National Health Service in England and Wales for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older. The company says Joenja is now available for use and funded in England through the Innovative Medicines Fund. In Wales, Joenja is e

TipRanks 15 days ago

PHAR

PHGUF
Pharming Group to report first quarter 2025 financial results on May 8

Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a uni

GlobeNewswire 15 days ago

PHAR

PHGUF
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final gu

GlobeNewswire 16 days ago

PHAR

PHGUF
European Opportunities: 3 Penny Stocks With Market Caps Larger Than €10M

As European markets navigate the challenges of escalating trade tensions and economic uncertainties, investors are increasingly looking for opportunities that offer both potential growth and resilience. Penny stocks, while often associated with speculation, still hold relevance as they represent smaller or emerging companies with the potential for significant value. By focusing on those with strong financial foundations, these stocks can present compelling opportunities for investors seeking...

Simply Wall St. 24 days ago

PHAR

PHGUF

SCE.DE
Exploring Three High Growth Tech Stocks In Europe

The European market has recently experienced significant declines, with the pan-European STOXX Europe 600 Index dropping 8.44% amid heightened trade tensions and economic uncertainty stemming from new U.S. tariffs. In this challenging environment, identifying high growth tech stocks in Europe requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving market conditions.

Simply Wall St. last month

BLV.PA

PHAR

PHGUF
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20

GlobeNewswire last month

PHAR

PHGUF
Pharming Group to participate in April investor conferences

Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April: Van Lanschot Kempen Life Sciences Conference 2025, Amsterdam, NL, April 2-3, 202524th Annual Needham Virtual Healthcare Conference, April 7-10, 2025Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present on Tuesday, April 8 at 1

GlobeNewswire last month

PHAR

PHGUF
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof

GlobeNewswire last month

PHAR

PHGUF
Pharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

GuruFocus.com last month

PHARM.AS
3 European Penny Stocks With Market Caps Over €300M

The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, there remains significant interest in penny stocks—a term that may seem outdated but continues to highlight opportunities for growth within smaller or newer companies. These stocks can be particularly attractive when they exhibit strong financial health and fundamentals, offering potential upside...

Simply Wall St. last month

GLVHF

DECB.BR

PHAR
Pharming Group Full Year 2024 Earnings: EPS Beats Expectations

Pharming Group ( AMS:PHARM ) Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023). Net...

Simply Wall St. last month

PHAR

PHGUF
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in the fi

GlobeNewswire last month

PHAR

PHGUF
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over

GlobeNewswire 2 months ago

PHAR

PHGUF
Pharming Group to participate in March investor conference

Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March: 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:3

GlobeNewswire 2 months ago

PHAR

PHGUF

Performance Overview

Return	PHGN.F	AEX-Index (^AEX)
YTD	-6.08%	+3.09%
1-Year	+1.26%	+0.17%
3-Year	+22.02%	+35.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pharming Group N.V. (PHGN.F)

Pharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...

Pharming Group reports first quarter 2025 financial results and provides business update

Earnings To Watch: Pharming Group (PHGUF) Reports Q1 2025 Result

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

Pharming announces positive recommendation from NICE for Joenja

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

European Opportunities: 3 Penny Stocks With Market Caps Larger Than €10M

Exploring Three High Growth Tech Stocks In Europe

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

3 European Penny Stocks With Market Caps Over €300M

Pharming Group Full Year 2024 Earnings: EPS Beats Expectations

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group to participate in March investor conference

Performance Overview